A Phase 1/2 interventional study of Tisotumab Vedotin (HuMax-TF-ADC) in Ovary Cancer, Cervix Cancer and Endometrium Cancer, sponsored by Seagen Inc.. Completed at 29 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-29.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Ovarian Neoplasms by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Ovarian Neoplasms · Pfizer.
Among the 38 studies in Ovarian Neoplasms by Pfizer, this one is the 6th largest by enrollment, is one of 3 that started in 2013, is one of 4 in phase 1/2, and was the 6th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →1 of the 38 studies in Ovarian Neoplasms by Pfizer is open now, in 7 countries. Recruiting first, the newest first:
Seagen, a wholly owned subsidiary of Pfizer · Sites in United States, France, Korea, Republic of and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 11 · Phase 3 5
First in 2003; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 195 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 52 across the 38 interventional studies. Of the 32 that completed or were terminated, 18 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
3 of the studies in Ovarian Neoplasms by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05059522Phase 3PfizerContinued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | 2026-12-31 |
| NCT04553133PfizerPF-07104091 as a Single Agent and in Combination Therapy | 2026-12-31 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Ovarian Neoplasms by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
The study is conducted in two parts. The dose escalation portion of the trial subjects are enrolled into cohorts at increasing dose levels of HuMax-TF-ADC in 21 day treatment cycles.
In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose of HuMax-TF-ADC as determined in Part 1
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All arms of the trial (borh in escalation and expansion phase) will be administered tisotumab vedotin (HuMax-TF-ADC)
Drug: Tisotumab Vedotin (HuMax-TF-ADC)
Also known as: TIVDAK
Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events
Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Time frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the dose escalation part.
Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events
Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Time frame: Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 325 days in the dose expansion part.
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Hematology Values
Number of participants with markedly abnormal hematology values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 hematology value. A markedly abnormal hematology value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Parts: Number of Participants With Markedly Abnormal Coagulation Values
Number of participants with markedly abnormal coagulation values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 coagulation value. A markedly abnormal coagulation value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Biochemistry Values
Number of participants with markedly abnormal biochemistry results were defined as all participants who experienced at least 1 CTCAE grade \>= 3 biochemistry value. A markedly abnormal biochemistry value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event of Special Interest
Bleeding adverse events of special interest included treatment emergent adverse events with preferred terms within the following standardised MedDRA queries (SMQs): Haemorrhage terms, excluding laboratory terms SMQ \[20000039\] (Broad) and Haemorrhage, laboratory terms SMQ \[20000040\] (Narrow). Bleeding adverse events of special interest were evaluated according to the NCI-CTCAE version 4.03. Bleeding events of all grades are included. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Number of Participants Who Experienced a Peripheral Neuropathy Event
Peripheral neuropathy events of special interest were evaluated according to the NCI-CTCAE version 4.03. Peripheral neuropathy events of all grades are included in the numbers below. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation Part: Clearance of Tisotumab Vedotin and Total HuMax-TF
Pharmacokinetic (PK) parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not collected to report or calculate clearance for the expansion phase.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: Volume of Distribution of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not planned to be collected for the volume of distribution of tisotumab vedotin and total HuMax-TF for the dose expansion part.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was only analyzed in the dose escalation part of the study. Data was not planned to be collected for the AUC0-inf of tisotumab vedotin and total HuMax-TF for the dose expansion part.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Maximum Observed Plasma Concentration (Cmax) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Time of Cmax (Tmax) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. t1/2 was only analyzed for the dose escalation part of the study. Data was not planned to be collected for t1/2 of tisotumab vedotin and total HuMax-TF for the dose expansion part.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: AUC0-t of Free Monomethyl Auristatin E (MMAE)
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: AUC0-inf of Free MMAE
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was not planned to be collected for the dose expansion part. AUC0-inf was not calculated where the percentage of the AUC that was due to the extrapolation was more than 20%.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Cmax of Free MMAE
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Tmax of Free MMAE
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation Part: PK Parameters, T 1/2 of Free MMAE
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study.
Time frame: Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
Dose Escalation and Expansion Part: Number of Participants With Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin
Participants who met the criterion for positive ADAs on treatment were defined as participants who were negative at baseline and had at least one positive post-baseline result, or participants who were positive at baseline and had at least one post baseline result with a titer higher than baseline.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage
Anti-tumor activity measured by the number of participants who experienced tumor shrinkage was not planned to be collected for the dose expansion part.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements
Anti-tumor activity measured by maximum reduction among available post-baseline sum of lesion measurements was not planned to be collected for the dose escalation part.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Percentage Change From Baseline in Prostate Specific Antigen (PSA)
PSA was only assessed in participants with castrate-resistant prostate cancer.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Percentage Change From Baseline in CA-125
In the dose escalation part, CA-125 was only assessed for participants with ovarian cancer. In the dose expansion part, CA-125 was intended to be assessed only for participants with ovarian and endometrium cancer, but was additionally assessed for some participants with NSCLC and cervical cancer.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Objective Response Rate
Objective Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Response assessment was investigator based for the escalation part and Independent Review Committee (IRC) based for the expansion part.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Escalation and Expansion Part: Disease Control Rate
Disease control rate was defined as the percentage of participants with CR, PR or stable disease (SD) as per investigator assessment per RECIST version 1.1 after 6, 12, 24 and 36 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease.
Time frame: At 6, 12, 24 and 36 weeks
Dose Escalation and Expansion Part: Progression Free Survival (PFS)
PFS was defined as the time in weeks from Day 1 in Cycle 1 to first disease progression or death, whichever occurred earliest, as assessed by the investigator. Only deaths that occurred within 60 days of the last visit were considered in the analysis and result are presented based on Kaplan-Meier estimates. Progression as defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase from nadir in the sum of diameters of target lesions, unequivocal progression in non-target lesions, or the appearance of new lesions
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
Dose Expansion Part: Duration of Response (DOR)
DOR was defined as the median time in weeks from when confirmed response was first documented until the first documented disease progression, or death from any cause, whichever was earliest as assessed by the investigator. A responder was defined as any participant with a best overall response of confirmed CR or PR.
Time frame: Day 1 to end of follow-up, up to a maximum of 60 weeks
| Milestone | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 15 | 55 | 14 | 15 | 15 | 36 | 18 |
| Completed 4 cycles of treatment | 0 | 1 | 1 | 2 | 0 | 2 | 2 | 1 | 5 | 31 | 6 | 4 | 6 | 22 | 7 |
| Completed 12 cycles of treatment | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 1 | 0 |
| Completed | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 0 |
| Not completed | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 6 | 15 | 53 | 14 | 15 | 14 | 35 | 18 |
| Withdrew: Disease progression | 2 | 2 | 3 | 2 | 3 | 2 | 3 | 3 | 7 | 40 | 5 | 9 | 9 | 20 | 9 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 3 | 3 | 1 | 2 | 1 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 4 | 6 | 4 | 0 | 3 | 5 | 6 |
| Withdrew: Other - miscellaneous | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 2 | 1 | 5 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Start of new anti-cancer treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Dose delay due to toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
| Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg |
|---|---|---|---|---|---|---|---|---|
| TEAEs | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 |
| Serious TEAEs | 2 | 1 | 0 | 2 | 2 | 2 | 2 | 4 |
| Infusion-Related TEAEs | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CTCAE Grade >=3 TEAEs | 2 | 3 | 1 | 1 | 2 | 3 | 2 | 4 |
| TEAEs Related to Study Drug | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 6 |
Number of participants with markedly abnormal hematology values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 hematology value. A markedly abnormal hematology value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
| Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Hematology Values | 2 | 1 | 1 | 0 | 2 | 2 | 0 | 1 | 0 | 23 | 0 | 3 | 1 | 5 | 3 |
Number of participants with markedly abnormal coagulation values was defined as all participants who experienced at least 1 CTCAE grade \>= 3 coagulation value. A markedly abnormal coagulation value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
| Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Parts: Number of Participants With Markedly Abnormal Coagulation Values | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 7 | 2 | 0 | 2 | 5 | 4 |
Number of participants with markedly abnormal biochemistry results were defined as all participants who experienced at least 1 CTCAE grade \>= 3 biochemistry value. A markedly abnormal biochemistry value was determined using the CTCAE grading systems based on National Cancer Institute (NCI)-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
| Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Part: Number of Participants With Markedly Abnormal Biochemistry Values | 2 | 1 | 3 | 0 | 1 | 0 | 1 | 2 | 4 | 8 | 4 | 6 | 2 | 9 | 4 |
| Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash | 1 | 0 | 0 | 2 | 0 | 2 | 2 | 4 | 3 | 6 | 2 | 2 | 2 | 8 | 5 |
Bleeding adverse events of special interest included treatment emergent adverse events with preferred terms within the following standardised MedDRA queries (SMQs): Haemorrhage terms, excluding laboratory terms SMQ \[20000039\] (Broad) and Haemorrhage, laboratory terms SMQ \[20000040\] (Narrow). Bleeding adverse events of special interest were evaluated according to the NCI-CTCAE version 4.03. Bleeding events of all grades are included. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
| Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event of Special Interest | 0 | 1 | 0 | 3 | 3 | 3 | 2 | 5 | 10 | 31 | 10 | 7 | 9 | 27 | 10 |
Peripheral neuropathy events of special interest were evaluated according to the NCI-CTCAE version 4.03. Peripheral neuropathy events of all grades are included in the numbers below. Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
| Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Part: Number of Participants Who Experienced a Peripheral Neuropathy Event | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 5 | 17 | 6 | 3 | 5 | 17 | 7 |
Pharmacokinetic (PK) parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not collected to report or calculate clearance for the expansion phase.
| mL/hr/kg | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg |
|---|---|---|---|---|---|---|---|---|
| Tisotumab Vedotin: Cycle 1 | — | 1.61 ± 7.79 | 1.46 ± 15.23 | 1.07 ± 11.60 | 1.84 ± 20.59 | 1.17 ± 60.05 | 1.56 ± 34.12 | 0.87 ± 8.93 |
| Tisotumab Vedotin: Cycle 2 | — | 1.72 ± 4.98 | 1.44 ± 6.32 | 1.07 ± 10.45 | 2.05 ± 26.80 | 0.93 ± 24.03 | 1.30 ± 19.06 | 1.03 ± 11.34 |
| Total HuMax-TF: Cycle 1 | — | 1.02 ± 0.20 | 0.98 ± 16.90 | 0.69 ± 12.61 | 1.26 ± 31.29 | 0.81 ± 69.72 | 0.87 ± 33.85 | 0.56 ± 14.13 |
| Total HuMax-TF: Cycle 2 | — | 1.05 ± 9.95 | 0.98 ± 6.52 | 0.71 ± 13.41 | 1.40 ± 31.39 | 0.53 ± 12.41 | 0.82 ± 26.45 | 0.61 ± 9.72 |
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not planned to be collected for the volume of distribution of tisotumab vedotin and total HuMax-TF for the dose expansion part.
| mL/kg | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg |
|---|---|---|---|---|---|---|---|---|
| Tisotumab Vedotin: Cycle 1 | — | 68.40 ± 11.84 | 70.80 ± 14.54 | 63.46 ± 16.87 | 86.10 ± 12.38 | 81.13 ± 35.60 | 92.04 ± 21.62 | 61.46 ± 18.07 |
| Tisotumab Vedotin: Cycle 2 | — | 76.69 ± 9.53 | 69.74 ± 7.99 | 62.61 ± 6.03 | 99.20 ± 20.82 | 70.21 ± 42.93 | 74.82 ± 4.19 | 72.74 ± 5.79 |
| Total HuMax-TF: Cycle 1 | — | 51.55 ± 1.61 | 60.27 ± 17.79 | 57.38 ± 8.65 | 77.55 ± 10.74 | 67.26 ± 50.61 | 68.69 ± 30.52 | 50.69 ± 7.20 |
| Total HuMax-TF: Cycle 2 | — | 55.75 ± 10.80 | 57.13 ± 8.90 | 58.48 ± 12.66 | 84.98 ± 22.85 | 50.62 ± 36.02 | 60.40 ± 17.48 | 58.10 ± 12.31 |
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
| day*ug/mL | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Pharmacokinetics (PK) Analysis Set |
|---|---|---|---|---|---|---|---|---|---|
| Tisotumab Vedotin: Cycle 1 | 2.5 ± 3.1 | 15.4 ± 8.2 | 25.1 ± 16.9 | 45.2 ± 9.3 | 33.1 ± 19.0 | 63.0 ± 49.3 | 52.3 ± 33.1 | 84.9 ± 33.7 | 79.31 ± 49.40 |
| Tisotumab Vedotin: Cycle 2 | 2.0 ± 15.7 | 9.9 ± 49.1 | 25.6 ± 7.1 | 45.2 ± 10.1 | 29.8 ± 25.1 | 42.7 ± 72.7 | 62.7 ± 21.5 | 86.3 ± 14.4 | 68.54 ± 55.49 |
| Total HuMax-TF: Cycle 1 | 2.9 ± 0.5 | 15.4 ± 53.1 | 35.0 ± 18.9 | 60.4 ± 13.4 | 44.9 ± 27.8 | 86.7 ± 54.3 | 85.9 ± 36.7 | 123.0 ± 34.7 | 112.70 ± 45.23 |
| Total HuMax-TF: Cycle 2 | 2.4 ± 12.3 | 14.4 ± 55.4 | 35.7 ± 7.1 | 58.8 ± 15.5 | 40.9 ± 26.2 | 60.2 ± 76.6 | 92.5 ± 33.4 | 133.6 ± 13.9 | 114.54 ± 45.83 |
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was only analyzed in the dose escalation part of the study. Data was not planned to be collected for the AUC0-inf of tisotumab vedotin and total HuMax-TF for the dose expansion part.
| day*ug/mL | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg |
|---|---|---|---|---|---|---|---|---|
| Tisotumab Vedotin: Cycle 1 | — | 15.57 ± 7.81 | 25.77 ± 15.70 | 46.68 ± 10.99 | 33.95 ± 20.93 | 63.88 ± 48.61 | 53.47 ± 30.88 | 105.84 ± 8.68 |
| Tisotumab Vedotin: Cycle 2 | — | 14.52 ± 4.98 | 26.12 ± 6.44 | 46.59 ± 9.98 | 30.56 ± 26.43 | 80.59 ± 24.03 | 64.10 ± 19.06 | 88.95 ± 11.04 |
| Total HuMax-TF: Cycle 1 | — | 23.75 ± 0.20 | 37.02 ± 16.39 | 69.96 ± 13.26 | 48.19 ± 35.67 | 90.08 ± 52.74 | 93.29 ± 30.45 | 157.81 ± 12.70 |
| Total HuMax-TF: Cycle 2 | — | 23.01 ± 9.95 | 37.08 ± 6.37 | 67.93 ± 14.25 | 43.41 ± 30.31 | 136.08 ± 12.41 | 98.59 ± 26.45 | 145.82 ± 9.42 |
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
| ug/mL | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Pharmacokinetics (PK) Analysis Set |
|---|---|---|---|---|---|---|---|---|---|
| Tisotumab Vedotin: Cycle 1 | 4.78 ± 12.35 | 12.20 ± 9.47 | 19.81 ± 17.32 | 34.67 ± 18.48 | 23.12 ± 21.10 | 35.42 ± 39.20 | 32.30 ± 22.08 | 55.53 ± 10.31 | 29.1 ± 34.1 |
| Tisotumab Vedotin: Cycle 2 | 3.85 ± 27.65 | 12.51 ± 11.51 | 20.25 ± 5.14 | 32.38 ± 7.11 | 21.84 ± 24.97 | 35.92 ± 30.39 | 44.30 ± 0.32 | 48.79 ± 26.37 | 26.1 ± 41.2 |
| Total HuMax-TF: Cycle 1 | 4.90 ± 13.00 | 11.84 ± 8.31 | 17.98 ± 11.64 | 29.30 ± 10.14 | 23.55 ± 25.16 | 30.57 ± 37.42 | 38.78 ± 21.77 | 58.02 ± 12.77 | 39.8 ± 31.1 |
| Total HuMax-TF: Cycle 2 | 3.96 ± 21.83 | 11.54 ± 8.83 | 16.90 ± 1.57 | 31.33 ± 8.13 | 22.11 ± 21.03 | 37.71 ± 42.96 | 43.40 ± 6.67 | 53.67 ± 19.75 | 38.3 ± 33.3 |
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
| hours | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Pharmacokinetics (PK) Analysis Set |
|---|---|---|---|---|---|---|---|---|---|
| Tisotumab Vedotin: Cycle 1 | 1.47 ± 72.74 | 1.18 ± 13.03 | 1.34 ± 11.77 | 1.15 ± 11.66 | 1.12 ± 9.55 | 1.18 ± 14.30 | 1.18 ± 7.45 | 1.11 ± 12.52 | 1.21 ± 364.12 |
| Tisotumab Vedotin: Cycle 2 | 1.54 ± 63.29 | 1.34 ± 6.27 | 1.32 ± 5.96 | 1.13 ± 11.18 | 1.21 ± 16.61 | 2.44 ± 35.75 | 1.14 ± 9.29 | 1.29 ± 7.55 | 1.44 ± 303.89 |
| Total HuMax-TF: Cycle 1 | 2.20 ± 49.15 | 1.18 ± 13.03 | 1.34 ± 11.77 | 1.15 ± 11.66 | 1.12 ± 9.55 | 1.18 ± 14.30 | 1.18 ± 7.45 | 1.11 ± 12.52 | 1.10 ± 397.92 |
| Total HuMax-TF: Cycle 2 | 2.19 ± 46.56 | 1.34 ± 6.27 | 1.32 ± 5.96 | 1.13 ± 11.18 | 1.21 ± 16.61 | 1.76 ± 50.43 | 1.14 ± 9.29 | 1.29 ± 7.55 | 1.15 ± 356.23 |
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. t1/2 was only analyzed for the dose escalation part of the study. Data was not planned to be collected for t1/2 of tisotumab vedotin and total HuMax-TF for the dose expansion part.
| hours | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg |
|---|---|---|---|---|---|---|---|---|
| Tisotumab Vedotin: Cycle 1 | 12.22 ± 11.61 | 29.53 ± 4.08 | 33.72 ± 6.26 | 41.06 ± 6.85 | 32.42 ± 20.05 | 47.89 ± 25.82 | 40.93 ± 11.48 | 41.19 ± 34.02 |
| Tisotumab Vedotin: Cycle 2 | 13.54 ± 5.50 | 23.50 ± 39.89 | 33.68 ± 1.74 | 40.44 ± 4.69 | 33.62 ± 14.50 | 32.15 ± 62.74 | 39.89 ± 23.15 | 48.93 ± 5.61 |
| Total HuMax-TF: Cycle 1 | 16.05 ± 27.93 | 28.66 ± 30.64 | 42.52 ± 7.48 | 57.37 ± 8.65 | 42.72 ± 34.62 | 57.72 ± 17.47 | 54.95 ± 5.32 | 55.10 ± 27.36 |
| Total HuMax-TF: Cycle 2 | 18.34 ± 8.73 | 30.71 ± 27.65 | 40.37 ± 4.27 | 56.77 ± 9.60 | 42.18 ± 25.39 | 46.24 ± 53.11 | 51.06 ± 9.18 | 66.05 ± 10.07 |
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
| day*ng/mL | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Pharmacokinetics (PK) Analysis Set |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 6.20 ± 72.05 | 12.61 ± 28.18 | 12.22 ± 67.23 | 11.63 ± 52.69 | 26.55 ± 44.24 | 22.55 ± 57.26 | 67.42 ± 59.98 | 26.47 ± 59.35 | 25.80 ± 93.91 |
| Cycle 2 | 3.19 ± 140.85 | 4.69 ± 87.27 | 14.89 ± 66.97 | 16.92 ± 58.12 | 21.51 ± 34.25 | 18.97 ± 52.14 | 36.20 ± 33.82 | 37.50 ± 43.08 | 23.48 ± 76.47 |
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was not planned to be collected for the dose expansion part. AUC0-inf was not calculated where the percentage of the AUC that was due to the extrapolation was more than 20%.
| day*ng/mL | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 12.63 ± 12.44 | 13.93 ± NA | 16.32 ± 57.56 | 20.39 ± NA | 27.08 ± 58.96 | 25.29 ± NA | 78.31 ± NA | 63.03 ± NA |
| Cycle 2 | — | — | 22.32 ± 43.62 | 31.40 ± NA | 31.43 ± NA | 33.23 ± NA | — | 58.95 ± NA |
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
| ng/mL | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Pharmacokinetics (PK) Analysis Set |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 0.760 ± 62.505 | 1.673 ± 30.756 | 1.524 ± 54.491 | 1.410 ± 19.149 | 2.807 ± 39.398 | 2.587 ± 29.172 | 6.351 ± 61.505 | 4.877 ± 31.350 | 3.16 ± 88.30 |
| Cycle 2 | 1.091 ± 74.293 | 1.342 ± 24.320 | 2.059 ± 51.470 | 2.243 ± 50.367 | 2.718 ± 39.492 | 2.035 ± 39.785 | 3.369 ± 36.875 | 4.704 ± 18.856 | 2.73 ± 78.69 |
PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
| hours | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Pharmacokinetics (PK) Analysis Set |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 23.88 ± 4.41 | 22.77 ± 16.56 | 24.39 ± 7.72 | 24.19 ± 5.52 | 25.07 ± 0.68 | 47.74 ± 114.28 | 83.24 ± 67.57 | 84.88 ± 61.54 | 154.28 ± 54.214 |
| Cycle 2 | 23.73 ± 5.78 | 24.05 ± 8.48 | 23.92 ± 13.04 | 24.94 ± 1.48 | 25.26 ± 0.76 | 46.24 ± 112.48 | 65.15 ± 104.61 | 47.12 ± 112.10 | 125.38 ± 31.21 |
PK parameters in plasma were determined based on non compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study.
| hours | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 95.15 ± 25.74 | 69.34 ± NA | 63.98 ± 2.24 | 62.58 ± NA | 63.65 ± 7.86 | 78.90 ± NA | 57.74 ± NA | 68.47 ± NA |
| Cycle 2 | — | — | 69.65 ± 3.86 | 60.71 ± NA | 70.20 ± NA | 78.94 ± NA | — | 63.92 ± NA |
Participants who met the criterion for positive ADAs on treatment were defined as participants who were negative at baseline and had at least one positive post-baseline result, or participants who were positive at baseline and had at least one post baseline result with a titer higher than baseline.
| Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Part: Number of Participants With Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 1 | 0 | 1 |
Anti-tumor activity measured by the number of participants who experienced tumor shrinkage was not planned to be collected for the dose expansion part.
| Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg |
|---|---|---|---|---|---|---|---|---|
| Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 3 |
Evaluation of treatment-emergent adverse events (TEAEs) includes number of participants with at least one: TEAE Serious TEAE Infusion-related TEAE Common Terminology Criteria for Adverse Events (CTCAE) grade \>=3 Treatment-related TEAE A CTCAE TEAE was determined using the CTCAE grading systems based on NCI-CTCAE version 4.03 assessed by the investigator per the below definitions. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.
| Participants | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|
| TEAEs | 15 | 55 | 14 | 15 | 15 | 36 | 18 |
| Serious TEAEs | 7 | 26 | 5 | 8 | 6 | 13 | 6 |
| Infusion-Related TEAEs | 1 | 1 | 1 | 1 | 2 | 0 | 0 |
| CTCAE Grade >=3 TEAEs | 9 | 30 | 8 | 8 | 10 | 16 | 11 |
| TEAEs Related to Study Drug | 15 | 54 | 13 | 14 | 14 | 36 | 18 |
Anti-tumor activity measured by maximum reduction among available post-baseline sum of lesion measurements was not planned to be collected for the dose escalation part.
| millimeter(s) | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|
| Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements | 6.00 (-127.0 to 41.0) | -8.50 (-64.0 to 50.0) | 1.00 (-11.0 to 26.0) | -2.00 (-51.0 to 40.0) | 0.00 (-59.0 to 31.0) | -4.00 (-41.0 to 115.0) | -1.00 (-11.0 to 15.0) |
PSA was only assessed in participants with castrate-resistant prostate cancer.
| Percentage Change in PSA | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Part: Percentage Change From Baseline in Prostate Specific Antigen (PSA) | — | 64.35 (64.35 to 64.35) | — | 40.91 (40.91 to 40.91) | 3.92 (3.92 to 3.92) | — | — | — | 60.07 (3.4 to 996.5) |
In the dose escalation part, CA-125 was only assessed for participants with ovarian cancer. In the dose expansion part, CA-125 was intended to be assessed only for participants with ovarian and endometrium cancer, but was additionally assessed for some participants with NSCLC and cervical cancer.
| Percentage Change | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Part: Percentage Change From Baseline in CA-125 | — | — | — | 18.75 (18.75 to 18.75) | — | -13.98 (-13.98 to -13.98) | 113.71 (113.71 to 113.71) | 11.62 (-22.7 to 45.9) | -25.17 (-88.7 to 240.5) | 37.85 (-46.1 to 666.2) | 180.94 (47.1 to 980.5) | 73.19 (-89.0 to 1924.4) |
Objective Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Response assessment was investigator based for the escalation part and Independent Review Committee (IRC) based for the expansion part.
| Percentage of Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Part: Objective Response Rate | 0 (0 to 71) | 0 (0 to 71) | 0 (0 to 71) | 33 (1 to 91) | 0 (0 to 71) | 0 (0 to 71) | 0 (0 to 71) | 0 (0 to 46) | 27 (8 to 55) | 24 (13 to 37) | 7 (0 to 34) | 13 (2 to 40) | 13 (2 to 40) | 14 (5 to 29) | 0 (0 to 19) |
Disease control rate was defined as the percentage of participants with CR, PR or stable disease (SD) as per investigator assessment per RECIST version 1.1 after 6, 12, 24 and 36 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease.
| Percentage of Participants | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 6 | 0 (0 to 71) | 33 (1 to 91) | 33 (1 to 91) | 67 (9 to 99) | 33 (1 to 91) | 100 (29 to 100) | 67 (9 to 99) | 50 (12 to 88) | 47 (21 to 73) | 60 (46 to 73) | 64 (35 to 87) | 40 (16 to 68) | 60 (32 to 84) | 72 (55 to 86) | 61 (36 to 83) |
| Week 12 | 0 (0 to 71) | 33 (1 to 91) | 33 (1 to 91) | 67 (9 to 99) | 0 (0 to 71) | 67 (9 to 99) | 33 (1 to 91) | 0 (0 to 46) | 33 (12 to 62) | 47 (34 to 61) | 43 (18 to 71) | 20 (4 to 48) | 13 (2 to 40) | 42 (26 to 59) | 28 (10 to 53) |
| Week 24 | 0 (0 to 71) | 33 (1 to 91) | 0 (0 to 71) | 33 (1 to 91) | 0 (0 to 71) | 0 (0 to 71) | 0 (0 to 71) | 0 (0 to 46) | 20 (4 to 48) | 18 (9 to 31) | 21 (5 to 51) | 7 (0 to 32) | 13 (2 to 40) | 14 (5 to 29) | 6 (0 to 27) |
| Week 36 | 0 (0 to 71) | 33 (1 to 91) | 0 (0 to 71) | 33 (1 to 91) | 0 (0 to 71) | 0 (0 to 71) | 0 (0 to 71) | 0 (0 to 46) | 7 (0 to 32) | 11 (4 to 22) | 0 (0 to 23) | 0 (0 to 22) | 7 (0 to 32) | 3 (0 to 15) | 6 (0 to 27) |
PFS was defined as the time in weeks from Day 1 in Cycle 1 to first disease progression or death, whichever occurred earliest, as assessed by the investigator. Only deaths that occurred within 60 days of the last visit were considered in the analysis and result are presented based on Kaplan-Meier estimates. Progression as defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase from nadir in the sum of diameters of target lesions, unequivocal progression in non-target lesions, or the appearance of new lesions
| Weeks | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation and Expansion Part: Progression Free Survival (PFS) | 5.1 (4.9 to 5.4) | 6.0 (3.9 to 49.1) | 6.1 (4.9 to NA) | 27.1 (6.0 to NA) | 6.1 (5.3 to 10.4) | 17.1 (11.3 to NA) | 12.3 (5.0 to 14.1) | 11.3 (2.1 to 11.3) | 11.0 (5.1 to 43.0) | 18.1 (9.3 to 23.0) | NA (5.1 to NA) | 10.1 (5.3 to 17.0) | 13.0 (5.1 to 17.3) | 13.0 (12.1 to 18.3) | 12.9 (7.1 to 23.7) |
DOR was defined as the median time in weeks from when confirmed response was first documented until the first documented disease progression, or death from any cause, whichever was earliest as assessed by the investigator. A responder was defined as any participant with a best overall response of confirmed CR or PR.
| Weeks | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dose Expansion Part: Duration of Response (DOR) | — | — | — | NA (NA to NA) | — | — | — | — | 32.0 (11.0 to 32.0) | 18.4 (13.1 to 41.7) | NA (NA to NA) | 18.3 (11.6 to 25.0) | NA (12.0 to NA) | 21.4 (13.1 to 29.6) | — |
Collected over Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The treatment duration ranged from 1 to 249 days in the escalation part and from 1 to 325 days in the expansion part.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation Part: 0.3 mg/kg | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose Escalation Part: 0.6 mg/kg | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation Part: 0.9 mg/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation Part: 1.2 mg/kg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose Escalation Part: 1.5 mg/kg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose Escalation Part: 1.8 mg/kg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose Escalation Part: 2.0 mg/kg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Dose Escalation Part: 2.2 mg/kg | 0/6 (0%) | 4/6 (66.7%) | 6/6 (100%) |
| Dose Expansion Part: Bladder Cancer | 0/15 (0%) | 7/15 (46.7%) | 15/15 (100%) |
| Dose Expansion Part: Cervical Cancer | 2/55 (3.6%) | 26/55 (47.3%) | 55/55 (100%) |
| Dose Expansion Part: Endometrial Cancer | 0/14 (0%) | 5/14 (35.7%) | 14/14 (100%) |
| Dose Expansion Part: Esophageal Cancer | 1/15 (6.7%) | 8/15 (53.3%) | 15/15 (100%) |
| Dose Expansion Part: Non-Small-Cell Lung Cancer | 1/15 (6.7%) | 6/15 (40%) | 15/15 (100%) |
| Dose Expansion Part: Ovarian Cancer | 2/36 (5.6%) | 13/36 (36.1%) | 36/36 (100%) |
| Dose Expansion Part: Prostate Cancer | 1/18 (5.6%) | 6/18 (33.3%) | 18/18 (100%) |
| Event | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small-Cell Lung Cancer | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/15 | 2/55 | 0/14 | 0/15 | 0/15 | 0/36 | 0/18 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/3 | 1/3 | 0/3 | 0/3 | 2/6 | 0/15 | 2/55 | 0/14 | 0/15 | 0/15 | 2/36 | 1/18 |
| Small intestinal obstructionGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/15 | 0/55 | 0/14 | 0/15 | 0/15 | 1/36 | 0/18 |
| Intestinal obstructionGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 1/3 | 0/6 | 0/15 | 0/55 | 0/14 | 0/15 | 0/15 | 0/36 | 0/18 |
| AscitesGastrointestinal disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/15 | 0/55 | 0/14 | 0/15 | 0/15 | 0/36 | 0/18 |
| GastritisGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/6 | 0/15 | 0/55 | 0/14 | 0/15 | 0/15 | 0/36 | 0/18 |
| Cystitis escherichiaInfections and infestations | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/15 | 0/55 | 0/14 | 0/15 | 0/15 | 0/36 | 0/18 |
| Klebsiella infectionInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/6 | 0/15 | 0/55 | 0/14 | 0/15 | 0/15 | 0/36 | 0/18 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/6 | 0/15 | 2/55 | 0/14 | 1/15 | 0/15 | 0/36 | 0/18 |
| General physical health deteriorationGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/6 | 0/15 | 0/55 | 0/14 | 1/15 | 0/15 | 1/36 | 0/18 |
| Event | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small-Cell Lung Cancer | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 3/3 | 2/3 | 3/3 | 2/3 | 4/6 | 13/15 | 28/55 | 11/14 | 8/15 | 11/15 | 30/36 | 12/18 |
| FatigueGeneral disorders | 3/3 | 1/3 | 1/3 | 1/3 | 0/3 | 3/3 | 0/3 | 4/6 | 8/15 | 29/55 | 10/14 | 10/15 | 8/15 | 15/36 | 15/18 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 3/3 | 1/3 | 2/3 | 0/3 | 1/3 | 1/3 | 3/6 | 1/15 | 13/55 | 2/14 | 3/15 | 2/15 | 0/36 | 3/18 |
| Decreased appetiteMetabolism and nutrition disorders | 1/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 5/6 | 3/15 | 20/55 | 5/14 | 6/15 | 5/15 | 12/36 | 10/18 |
| NauseaGastrointestinal disorders | 1/3 | 0/3 | 1/3 | 1/3 | 0/3 | 1/3 | 1/3 | 4/6 | 7/15 | 25/55 | 7/14 | 7/15 | 10/15 | 20/36 | 12/18 |
| ConstipationGastrointestinal disorders | 2/3 | 0/3 | 0/3 | 0/3 | 1/3 | 2/3 | 1/3 | 3/6 | 6/15 | 19/55 | 3/14 | 6/15 | 5/15 | 11/36 | 9/18 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 1/3 | 0/3 | 1/3 | 0/3 | 0/3 | 2/3 | 0/6 | 3/15 | 17/55 | 6/14 | 2/15 | 4/15 | 14/36 | 5/18 |
| StomatitisGastrointestinal disorders | 0/3 | 0/3 | 2/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/6 | 1/15 | 0/55 | 1/14 | 0/15 | 0/15 | 6/36 | 2/18 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/3 | 2/3 | 1/3 | 1/3 | 0/3 | 0/6 | 0/15 | 5/55 | 1/14 | 0/15 | 1/15 | 4/36 | 0/18 |
| PyrexiaGeneral disorders | 2/3 | 0/3 | 1/3 | 1/3 | 0/3 | 0/3 | 0/3 | 4/6 | 2/15 | 11/55 | 1/14 | 2/15 | 0/15 | 4/36 | 0/18 |
Full analysis set: all participants who had been exposed to tisotumab vedotin in either the dose escalation or expansion parts.
| Age, Customized(Participants) | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In utero | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adolescents (12-17 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adults (18-64 years) | 3 | 1 | 3 | 3 | 2 | 2 | 2 | 4 | 12 | 51 | 8 | 8 | 9 | 26 | 4 | 138 |
| From 65-84 years | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 2 | 3 | 4 | 6 | 7 | 6 | 10 | 14 | 57 |
| 85 years and over | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 5 | 2 | 55 | 14 | 3 | 12 | 36 | 0 | 140 |
| Male | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 1 | 13 | 0 | 0 | 12 | 3 | 0 | 18 | 55 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Not Hispanic or Latino | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 15 | 53 | 13 | 15 | 15 | 35 | 18 | 191 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation Part: 0.3 mg/kg | Dose Escalation Part: 0.6 mg/kg | Dose Escalation Part: 0.9 mg/kg | Dose Escalation Part: 1.2 mg/kg | Dose Escalation Part: 1.5 mg/kg | Dose Escalation Part: 1.8 mg/kg | Dose Escalation Part: 2.0 mg/kg | Dose Escalation Part: 2.2 mg/kg | Dose Expansion Part: Bladder Cancer | Dose Expansion Part: Cervical Cancer | Dose Expansion Part: Endometrial Cancer | Dose Expansion Part: Esophageal Cancer | Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) | Dose Expansion Part: Ovarian Cancer | Dose Expansion Part: Prostate Cancer | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 15 | 49 | 14 | 13 | 13 | 34 | 17 | 182 |
| Black or Asian American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 1 | 0 | 0 | 5 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2013 to primary completion in May 2019, 65 months.
Results were first posted in Dec 2021, 2 years 7 months after primary completion. A results delay was requested in Apr 2020.
Of 116 industry-sponsored phase 1/2 interventional studies under Ovarian Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 88. This study's 65 months is close to that.
Counting every sponsor, half of 173 studies reached it within 65 months; a quarter within 44 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tisotumab vedotin